Artiklar
Gaucher disease in children
Real-World Evidence and Phase IV studies in CRSwNP
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.
DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP
The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3
Efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities
RSV-prevention med Beyfortus (nirsevimab) – tillgänglig för nyfödda från 10 september
Beyfortus® är en RSV-immunisering designad för alla spädbarn, för skydd mot RSV-sjukdom i de nedre luftvägarna (LRTD).1
Defining ITP
Low platelet counts are one facet of ITP, but when we look at it from another angle, we see the multiple dimensions of ITP. ITP is a condition of complex immune dysregulation that reduces platelet counts—causing bleeding, bruising, fatigue, and other health-related quality-of-life (HRQoL) issues—while increasing inflammation and the risk of thromboembolic events (TEs).1-5
Living with ITP
Patients reported significant quality of life (QoL) challenges related to their ITP1
Assessing fatigue in ITP patients
For ITP patients, several scales are available to measure and track fatigue and its impact on quality of life. These tools can help patients and healthcare providers gauge symptoms and adjust their ITP treatment accordingly.1-4
Mechanism of Disease
Complex immune dysregulation can lead to autoimmunity and inflammation1-6
FLUNITY-HD : the largest individually randomised influenza vaccine effectiveness study of its kind.
FLUNITY-HD is the largest individually randomised influenza vaccine effectiveness study, with nearly half a million older adults across multiple seasons.1